The International Generic and Biosimilar Medicines Association (IGBA), giving voice to the manufacturers of quality-assured, safe, and cost-effective generic and biosimilar medicines, welcomes the World Health Organization Executive Board’s focus on the Three Billion Targets in the EB154 agenda, linking the learnings from the General Programme of Work 13 (GPW13) to the newly developed GPW14 to accelerate progress in global health.

The generic and biosimilar medicines industry globally, represented by the International Generic and Biosimilar medicines Association (IGBA), supplies the overwhelming majority of prescription medicines to patients worldwide, and strongly supports ongoing multilateral efforts to achieve a robust WHO Pandemic Agreement.

IGBA welcomes the opportunity to provide comments to the 30 October 2023 proposal for negotiating text of the WHO Pandemic Agreement. As the international representative organization of the generic and biosimilar medicines industry, IGBA joins the WHO and Member States in reaffirming the importance of multisectoral collaboration to safeguard human health and build stronger, more resilient health systems.